샘플 요청 목록

 카트 문의
시장보고서
상품코드
1786513

세계의 에르도스테인(Erdosteine) 시장

Erdosteine
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 274 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

에르도스테인 세계 시장은 2030년까지 7,360만 달러에 달할 전망

2024년에 5,260만 달러로 추정되는 에르도스테인 세계 시장은 2024-2030년 분석 기간에 CAGR 5.8%로 성장하여 2030년에는 7,360만 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 기관지염은 CAGR 5.1%를 기록하며 분석 기간 종료시에는 2,930만 달러에 달할 것으로 예측됩니다. COPD 부문의 성장률은 분석 기간 동안 CAGR 5.1%로 추정됩니다.

미국 시장은 1,430만 달러로 추정, 중국은 CAGR 8.9%로 성장 예측

미국의 에르도스테인 시장은 2024년에는 1,430만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 분석 기간 2024년부터 2030년까지 CAGR 8.9%로 성장하여 2030년에는 예측 시장 규모 1,480만 달러에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 2.9%와 5.6%로 예측됩니다. 유럽에서는 독일이 CAGR 3.7%로 성장할 것으로 예측됩니다.

세계의 에르도스테인 시장 - 주요 동향과 촉진요인 정리

에르도스테인이 호흡기 치료에서 주목받는 이유는?

만성 호흡기질환 치료에 널리 사용되는 점액 용해제인 에르도스테인은 만성폐쇄성폐질환(COPD), 기관지염, 천식 등의 질환 관리에 효과적이기 때문에 점점 더 인기를 얻고 있습니다. 점액의 점도를 낮추고, 가래를 쉽게 배출하고, 기도 청소율을 개선하여 효과를 발휘합니다. 대기오염, 흡연, 고령화로 인해 호흡기질환의 유병률이 높아지면서 에르도스테인 기반 약품에 대한 수요는 증가하는 추세입니다.

임상 연구에서도 에르도스테인의 항염증 및 항산화 작용이 강조되어 호흡기질환에 대한 병용요법으로 선호되고 있습니다. 특히 만성 폐질환 환자를 중심으로 병원과 재택 진료 모두에서 처방이 증가하고 있습니다. 규제 당국의 승인과 효능에 대한 인식이 높아지면서 시장 확대에 더욱 박차를 가하고 있습니다.

제형 기술 혁신을 통한 에르도스테인 치료의 개선은?

제약사들은 생체이용률과 환자 순응도를 높일 수 있는 고급 에르도스테인 제제 개발에 집중하고 있습니다. 다양한 환자의 요구를 충족시키기 위해 발포성 정제, 방출 제어 캡슐, 액상 제제가 도입되었습니다.

또한, 장기적인 COVID 관련 폐 합병증을 포함한 바이러스 감염 후 호흡기 증후군 관리에서 에르도스테인의 가능성을 조사하고 있습니다. 에르도스테인과 다른 기관지확장제 및 코르티코스테로이드와의 병용은 치료 결과를 최적화하기 위해 연구되고 있습니다. 호흡기 치료가 발전함에 따라 에르도스테인의 폐질환 관리 역할은 더욱 확대될 것으로 예상됩니다.

에르도스테인 시장의 성장을 촉진하는 주요 요인은 무엇인가?

에르도스테인 시장의 성장은 호흡기질환의 유병률 증가, 약물 제제의 발전, 효과적인 점액 용해제에 대한 수요 증가로 인해 발생합니다. 노인 인구의 증가와 대기오염의 증가는 COPD와 기관지염의 증가에 기여하고 있으며, 이는 에르도스테인의 채택에 박차를 가하고 있습니다.

호흡기 건강 증진을 위한 정부의 노력과 에르도스테인의 광범위한 치료 가능성에 대한 제약 연구 확대는 시장 성장을 더욱 가속화시키고 있습니다. 새로운 제형과 병용요법이 등장함에 따라 에르도스테인은 호흡기 치료 프로토콜에서 중요한 역할을 할 것으로 기대됩니다.

부문

용도(기관지염, COPD, 비인두염, 기타), 최종 용도(제약회사, CMO, 조사기관)

조사 대상 기업 사례

  • Alfa Chemistry
  • Aurore Life Sciences
  • BOC Sciences
  • Hwail Pharmaceutical
  • Manus Aktteva Biopharma LLP
  • Recipharm AB
  • Reine Lifescience
  • SimSon Pharma Limited
  • Taj Pharmaceuticals Ltd.
  • United States Biological

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 일반적인 LLM 및 업계별 SLM 쿼리를 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.08.14

Global Erdosteine Market to Reach US$73.6 Million by 2030

The global market for Erdosteine estimated at US$52.6 Million in the year 2024, is expected to reach US$73.6 Million by 2030, growing at a CAGR of 5.8% over the analysis period 2024-2030. Bronchitis, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$29.3 Million by the end of the analysis period. Growth in the COPD segment is estimated at 5.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$14.3 Million While China is Forecast to Grow at 8.9% CAGR

The Erdosteine market in the U.S. is estimated at US$14.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$14.8 Million by the year 2030 trailing a CAGR of 8.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 5.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Global Erdosteine Market - Key Trends & Drivers Summarized

Why Is Erdosteine Gaining Prominence in Respiratory Treatments?

Erdosteine, a mucolytic agent widely used for treating chronic respiratory diseases, is becoming increasingly popular due to its effectiveness in managing conditions such as chronic obstructive pulmonary disease (COPD), bronchitis, and asthma. It works by reducing mucus viscosity, facilitating easier expectoration, and improving airway clearance. With the rising prevalence of respiratory disorders due to air pollution, smoking, and aging populations, demand for Erdosteine-based medications is on the rise.

Clinical research has also highlighted Erdosteine’s anti-inflammatory and antioxidant properties, making it a preferred choice in combination therapies for respiratory conditions. The drug is being increasingly prescribed in both hospital and home-care settings, particularly for patients with chronic lung diseases. Regulatory approvals and growing awareness of its benefits are further driving market expansion.

How Are Innovations in Drug Formulation Improving Erdosteine Treatments?

Pharmaceutical companies are focusing on developing advanced Erdosteine formulations that enhance bioavailability and patient adherence. Effervescent tablets, controlled-release capsules, and liquid formulations are being introduced to cater to different patient needs.

Additionally, research is exploring Erdosteine’s potential in post-viral respiratory syndrome management, including long COVID-related lung complications. The combination of Erdosteine with other bronchodilators and corticosteroids is being investigated to optimize treatment outcomes. As advancements in respiratory care continue, Erdosteine’s role in pulmonary disease management is expected to expand.

What Are the Key Factors Driving Growth in the Erdosteine Market?

The growth in the Erdosteine market is driven by increasing respiratory disease prevalence, advancements in drug formulation, and rising demand for effective mucolytic agents. The growing elderly population, coupled with higher air pollution levels, is contributing to increased cases of COPD and bronchitis, fueling Erdosteine adoption.

Government initiatives promoting respiratory health and the expansion of pharmaceutical research into Erdosteine’s broader therapeutic potential are further accelerating market growth. As new formulations and combination therapies emerge, Erdosteine is expected to play a crucial role in respiratory treatment protocols.

SCOPE OF STUDY:

The report analyzes the Erdosteine market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Application (Bronchitis, COPD, Nasopharyngitis, Others); End-Use (Pharmaceuticals, CMOs, Research institutes)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • Alfa Chemistry
  • Aurore Life Sciences
  • BOC Sciences
  • Hwail Pharmaceutical
  • Manus Aktteva Biopharma LLP
  • Recipharm AB
  • Reine Lifescience
  • SimSon Pharma Limited
  • Taj Pharmaceuticals Ltd.
  • United States Biological

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Erdosteine - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Chronic Respiratory Diseases Spurs Demand for Erdosteine-Based Therapies
    • Increasing Geriatric Population Strengthens Business Case for Mucolytic Drug Adoption
    • Growth in Smoking-Related Ailments Expands Addressable Market Opportunity for Erdosteine
    • Adoption of Preventive Healthcare Practices Drives Demand for Long-Term Respiratory Medications
    • Rising Air Pollution Levels Throws the Spotlight on Respiratory Health Solutions
    • Regulatory Support for Mucolytics in Europe Drives Erdosteine Market Penetration
    • Growing Focus on Patient-Centric Drug Delivery Systems Enhances Market Appeal of Erdosteine
    • Expansion of Pulmonary Rehabilitation Programs Accelerates Use of Adjunct Mucolytic Therapies
    • Shift Towards Evidence-Based Prescriptions Sustains Growth in Erdosteine Adoption
    • Increasing Healthcare Spending in Emerging Markets Propels Growth of Erdosteine Consumption
    • Advancements in Formulation Technology Drive Adoption of Sustained-Release Erdosteine Products
    • Rising Demand for Antibiotic-Sparing Therapies Strengthens Market Position of Erdosteine
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Erdosteine Market Analysis of Annual Sales in US$ for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Erdosteine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Erdosteine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Erdosteine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Bronchitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Bronchitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Bronchitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for COPD by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for COPD by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for COPD by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Nasopharyngitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Nasopharyngitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Nasopharyngitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Others by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Pharmaceuticals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Pharmaceuticals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Pharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for CMOs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for CMOs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for CMOs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Research institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Research institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Research institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Erdosteine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
  • JAPAN
    • Erdosteine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
  • CHINA
    • Erdosteine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
  • EUROPE
    • Erdosteine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Erdosteine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Erdosteine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Erdosteine by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
  • FRANCE
    • Erdosteine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
  • GERMANY
    • Erdosteine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Erdosteine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 85: Spain 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 91: Russia 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Erdosteine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Erdosteine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Erdosteine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Erdosteine by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Erdosteine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 112: Australia 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
  • INDIA
    • Erdosteine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 118: India 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 124: South Korea 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Erdosteine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Erdosteine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Erdosteine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Erdosteine by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 145: Argentina 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 151: Brazil 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 157: Mexico 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Erdosteine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Erdosteine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Erdosteine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Erdosteine by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 178: Iran 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 184: Israel 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 196: UAE 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
  • AFRICA
    • Erdosteine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 208: Africa 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제